{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:25:02Z","timestamp":1788866702358,"version":"build-2803163510"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prior to 2017, heroin and other prescription opioids were the most prevalent opioids implicated in driving under the influence of drugs (DUID) investigation cases, and fentanyl was rarely included in the scope of toxicological analysis. Fentanyl has become the most frequently identified opioid in DUID cases, with many suspected heroin cases turning out to be only fentanyl. A review of fentanyl-positive DUID cases at NMS Labs was performed to provide prevalence information, change in concentration, patterns of combined drug use, indicators of impairment and driving behavior in order to assist with the toxicological interpretation of DUID scenarios involving fentanyl. Fentanyl-positive DUID cases received between January 2010 and December 2020 were examined. Blood results were confirmed and quantitated for fentanyl, norfentanyl and acetylfentanyl using a liquid chromatography--tandem mass spectrometry analysis with a limit of quantitation of 0.10, 0.20 and 0.10\u2009ng\/mL, respectively. Of 153,234 blood cases examined for DUID over 11\u2009years, fentanyl was confirmed positive in 6,779 (4.4%) cases. However, there were significant changes in positivity over time. Fentanyl percentage positivity increased from 0.60% in 2010 to 12% in 2020. Of 5,976 confirmed fentanyl-positive cases in 2018\u20132020, blood concentrations &amp;gt;4.0\u2009ng\/mL were observed in 44% (2018), 55% (2019) and 59% (2020) of cases. Polypharmacy was common with 87% of blood samples confirmed positive for fentanyl and at least one other compound. Stimulant was the most commonly identified drug class in cases where at least one additional drug class was present. This study illustrates the importance of including fentanyl in a routine blood DUID panel.<\/jats:p>","DOI":"10.1093\/jat\/bkab049","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T03:14:36Z","timestamp":1621307676000},"page":"337-341","source":"Crossref","is-referenced-by-count":16,"title":["11-Year Study of Fentanyl in Driving Under the Influence of Drugs Casework"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9691-3397","authenticated-orcid":false,"given":"Ayako","family":"Chan-Hosokawa","sequence":"first","affiliation":[{"name":"NMS Labs, 200 Welsh Rd, Horsham, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene J","family":"Bierly","sequence":"additional","affiliation":[{"name":"NMS Labs, 200 Welsh Rd, Horsham, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"2022032114035262700_R1","article-title":"Fentanyl and Fentanyl-Related Substances Reported in NFLIS, 2015\u20132016","author":"NFLIS Brief"},{"key":"2022032114035262700_R2","article-title":"Opioid Overdose. Overdose Waves","author":"Centers for Disease Control and Prevention"},{"key":"2022032114035262700_R3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jat\/bkaa105","article-title":"Fentanyl and driving impairment","volume":"45","author":"Rohrig","year":"2020","journal-title":"Journal of Analytical Toxicology"},{"key":"2022032114035262700_R4","first-page":"439","article-title":"Fentanyl: a review for clinical and analytical toxicologists","volume":"33","author":"Poklis","year":"1995","journal-title":"Journal of Clinical Toxicology"},{"key":"2022032114035262700_R5","first-page":"844","volume-title":"Disposition of Toxic Drugs and Chemicals in Man","author":"Baselt","year":"2020","edition":"12th"},{"key":"2022032114035262700_R6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/BF03178274","article-title":"Transdermal fentanyl: pharmacology and toxicology","volume":"5","author":"Nelson","year":"2009","journal-title":"Journal of Medical Toxicology"},{"key":"2022032114035262700_R7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.drugpo.2017.05.029","article-title":"Epidemiology of fentanyl-involved drug overdose deaths: a geospatial retrospective study in Rhode Island, USA","volume":"46","author":"Marshall","year":"2017","journal-title":"International Journal of Drug Policy"},{"key":"2022032114035262700_R8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0885-3924(02)00539-0","article-title":"Driving ability under long-term treatment with transdermal fentanyl","volume":"25","author":"Sabatowski","year":"2003","journal-title":"Journal of Pain and Symptom Management"},{"key":"2022032114035262700_R9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/00004424-198609000-00008","article-title":"Driving ability after intravenous fentanyl or diazepam. A controlled double-blind study.","volume":"21","author":"Stevenson","year":"1986","journal-title":"Investigative Radiology"},{"key":"2022032114035262700_R10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/PAF.0000000000000622","article-title":"Xylazine, a veterinary tranquilizer, detected in 42 accidental fentanyl intoxication deaths","volume":"42","author":"Nunez","year":"2021","journal-title":"The American Journal of Forensic Medicine and Pathology"},{"key":"2022032114035262700_R11","doi-asserted-by":"crossref","DOI":"10.1136\/injuryprev-2020-043968","article-title":"Increasing presence of xylazine in heroin and\/or fentanyl deaths, Philadelphia, Pennsylvania 2010\u20132019","author":"Johnson","year":"2021"},{"key":"2022032114035262700_R12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","article-title":"Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature","volume":"240","author":"Ruiz-Colon","year":"2014","journal-title":"Forensic Science International"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkab049\/38673313\/bkab049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/46\/3\/337\/42961798\/bkab049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/46\/3\/337\/42961798\/bkab049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T14:28:30Z","timestamp":1647872910000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/46\/3\/337\/6277593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,5,18]]},"published-print":{"date-parts":[[2022,3,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkab049","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,5,18]]}}}